Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia

Current Opinion in Hematology

Volumn 18, Issue 2, 2011, Pages 98-104

  Parmar, Simrit ^a   Fernandez Vina, Marcelo ^a   De Lima, Marcos ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

acute myeloid leukemia; allogeneic stem cell transplant; graft versus host disease; graft versus leukemia

Indexed keywords

5,6 DIHYDROAZACITIDINE; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; DNA METHYLTRANSFERASE INHIBITOR; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEPTIDE DERIVATIVE; PLERIXAFOR; PR1 PEPTIDE; RAPAMYCIN; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; GENE ACTIVATION; GENE OVEREXPRESSION; GENOTYPE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; SOLID TUMOR; T CELL DEPLETION; TREATMENT RESPONSE;

ACUTE DISEASE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 79952036903     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328343b858     Document Type: Article

References (56)

1. Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115:1850-1857.
2. Ruggeri L, Capanni M, Urbani E, etal. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-2100. (Pubitemid 34229476)
3. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102:814-819. (Pubitemid 36917769)
4. Ljunggren HG, Karre K. In search of the'missing self: MHC molecules and NK cell recognition. Immunol Today 1990; 11:237-244. (Pubitemid 20198988)
5. Yawata M, YawataN, Draghi M, etal. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203:633-645.
6. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR • haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; 113:726-732.
7. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA- identical sibling hematopoietic stem-cell transplantation for acute myelogen ous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105:4878-4884. (Pubitemid 40807317)
8. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116:2411-2419.
9. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5:201-214. (Pubitemid 40364822)
10. Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007; 21:2145-2152. (Pubitemid 47423804)
11. Stringaris K, Adams S, Uribe M, et al. Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant 2010; 16:1257-1264.
12. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-3057.
13. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine •• the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28:955-959.
14. Richard Champlin DAL, Fernandez-Vina M, Rondon G, et al. Alloreactive NK cells to augment antileukemia cytotoxicity with allogeneic stem cell transplantation for AML/MDS: a phase I study. Blood (ASH Annual Meeting Abstracts) 2010; 116:abstract 489.
15. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20:405-412. (Pubitemid 34072522)
16. Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002; 9:123-137. (Pubitemid 34457331)
17. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41:483-493. (Pubitemid 351386713)
18. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15:433-444. (Pubitemid 27074209)
19. Yegin ZA, Ozkurt ZN, Aki SZ, Sucak GT. Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation. Transfus Apher Sci 2010; 42:239-245.
20. Massenkeil G, Nagy M, Lawang M, et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003; 31:339-345. (Pubitemid 36410679)
21. Dey BR, McAfee S, Colby C, et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9:320-329. (Pubitemid 38351817)
22. Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004; 103:790-795. (Pubitemid 38129534)
23. Huang XJ, Liu DH, Liu KY, etal. Donor lymphocyte infusion forthe treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92:414-417.
24. Raiola AM, Van Lint MT, Valbonesi M, et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003; 31:687-693. (Pubitemid 36553479)
25. Borchers S, Provasi E, Benati C, etal. Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation. Hum Gene Ther 2010 [Epub ahead of print].
26. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308. (Pubitemid 351430867)
27. Yazaki M, Takahashi T, Andho M, et al. A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes. Bone Marrow Transplant 1999; 24:129-137. (Pubitemid 29351826)
28. + T cell clones specific for the minor histocompatibility antigen H-Y, after in vitro priming of human T cells by HLA-identical monocyte-derived dendritic cells. Transplantation 2001; 71:1449-1455. (Pubitemid 32507120)
29. Amrolia PJ, Reid SD, Gao L, et al. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 2003; 101:1007-1014. (Pubitemid 36139373)
30. Stauss HJ, Thomas S, Cesco-Gaspere M, et al. WT1 -specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis 2008; 40:113-116. (Pubitemid 350192301)
31. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006; 107:2099-2107. (Pubitemid 44665642)
32. Falkenburg JH, Marijt WA, Heemskerk MH, Willemze R. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions. Curr Opin Hematol 2002; 9:497-502. (Pubitemid 35191118)
33. Mutis T, Schrama E, Melief CJ, Goulmy E. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. Blood 1998; 92:1677-1684. (Pubitemid 28406872)
34. HeemskerkMH, Hoogeboom M, Hagedoorn R, etal. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004; 199:885-894. (Pubitemid 38481080)
35. Yamagami T, Sugiyama H, Inoue K, etal. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87:2878-2884. (Pubitemid 26102238)
36. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95:2198-2203. (Pubitemid 30167714)
37. + T lymphocytes in an HLA class II-restricted manner. Blood 2005; 106:1415-1418. (Pubitemid 41129609)
38. Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/ SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005; 106:3062-3067. (Pubitemid 41565901)
39. Rezvani K. PR1 vaccination in myeloid malignancies. Expert Rev Vaccines 2008; 7:867-875.
40. Ma Q, Wang C, Jones D, et al. Adoptive transfer of PR1 cytotoxic T • lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 2010; 12:1056-1062.
41. Alatrash G, Molldrem JJ. Immunotherapy of AML. Cancer Treat Res 2010; • 145:237-255.
42. Smits EL, Berneman ZN, Van Tendeloo VF. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist 2009; 14:240-252.
43. De Rijke B, van Horssen-Zoetbrood A, Beekman JM, et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest 2005; 115:3506-3516. (Pubitemid 43121838)
44. Norde WJ, Overes IM, Maas F, etal. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Blood 2009; 113:231 2-2323.
45. Schleuning M, Judith D, Jedlickova Z, et al. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant 2009; 43:717-723.
46. Brunstein CG, Miller JS,CaoQ, etal. Infusion of ex vivo expanded T regulatory •• cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2010 [Epub ahead of print].
47. Partow Kebriaei SG, Jones D, Gutierrez K, et al. Addition of umbilical cord blood (UCB) unit to reduced intensity conditioning (RIC) regimen to augment graft versus tumor (GVT) in patients (pts) with advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 2008; 112:abstract 3297.
48. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004; 104:550-557. (Pubitemid 38900040)
49. Fukuda S, Broxmeyer HE, Pelus LM. Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/ CXCR4 axis. Blood 2005; 105:3117-3126.
50. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in • leukemia and other cancers. Leukemia 2009; 23:43-52.
51. Konopleva M, Zhihong Z, Wang R-U, et al. A phase I/II trial of plerixafor/G-CSF combined with IV Bu/Flu conditioning regimen in AML/MDS patients undergoing allogenic stem cell transplantation Blood (ASH Annual Meeting Abstracts) 2010; 116:abstract 2358.
52. Thakar MS, Forman SJ. ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse? Hematology Am Soc Hematol Educ Program 2009; 1:414-418.
53. Kantarjian HM, O'Brien S, Huang X, etal. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007; 109:1133-1137. (Pubitemid 46435392)
54. De Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low- •• dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010; 116:5420-5431.
55. Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009; 115:1899-1905.
56. Uwe Platzbecker MW, Radke J, Kiani A, etal. Minimal residual disease (MRD) based preemptive 5-azacytidine treatment can prevent or delay imminent relapse in patients with high-risk MDS or AML after allogenic HSCT - results of the 'RELAZA' Trial. Blood (ASH Annual Meeting Abstracts) 2010; 116: abstract 679.